Concepedia
Statistics
Publications
5
Citations
216
H-Index
Active since
2003
Affiliations
Northwestern University(Current)
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Novartis (Switzerland)
Oregon Health & Science University
Northwestern Memorial Hospital
Mary Beth Riley is an author at Northwestern University specializing in medicine, hematologic oncology, and hematology.
Publications per year
2003–2004
Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older
Chadi Nabhan, Lynn M. Rundhaugen, Mary Beth Riley et al. · Leukemia Research · 2004 · 75 citations
Medicine, Hematology, Oncology +12
Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old
Simrit Parmar, Lynn M. Rundhaugen, Larry Boehlke et al. · Leukemia Research · 2004 · 57 citations
Medicine, Hematology, Oncology +16
Chronic Myeloid Leukemia Following Therapy with Imatinib Mesylate (Gleevec)
John L. Frater, Martin S. Tallman, Daina Variakojis et al. · American Journal of Clinical Pathology · 2003 · 37 citations
Medicine, Hematology, Oncology +17
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease
Chadi Nabhan, Lynn M. Rundhaugen, Mah Noor Jatoi et al. · Annals of Oncology · 2004 · 28 citations · Full text
Pharmacy, Pharmacotherapy, Pathophysiology +3
Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status
Debra Resta, Martin S. Tallman, Mary Beth Riley et al. · American Journal of Clinical Pathology · 2003 · 19 citations
Medicine, Hematology, Pathology +17
1–5 of 5